In a move that could reshape how medicines are discovered, AI startup Chai Discovery has announced a partnership with pharmaceutical giant Eli Lilly, just months after securing a $1.3 billion valuation. The deal, which leverages Chai’s proprietary algorithm called Chai-2 to design antibodies, represents one of the most significant collaborations between traditional pharma and AI-driven biotech to date. But as the industry races to adopt these technologies, questions about infrastructure demands, ethical oversight, and whether AI can truly deliver on its promise are coming into sharp focus.
The Rise of AI-Powered Drug Discovery
Chai Discovery’s journey from OpenAI’s offices to a major pharmaceutical partnership reads like a Silicon Valley success story. Founded in 2024 by former OpenAI researcher Josh Meier and Stripe engineer Jack Dent, the company has raised hundreds of millions in just over a year, with backing from influential investors including General Catalyst. Their algorithm, described as a “computer-aided design suite” for molecules, aims to accelerate the notoriously slow and expensive drug discovery process.
“We believe the biopharma companies that move the most quickly to partner with companies like Chai will be the first to get molecules into the clinic,” said Elena Viboch, managing director at General Catalyst. “In practice that means partnering in 2026 and by the end of 2027 seeing first-in-class medicines enter into clinical trials.”
The Infrastructure Challenge
As AI companies like Chai push computational boundaries, they’re running into a fundamental constraint: power. The Trump administration’s recent proposal for tech companies to purchase $15 billion worth of power plants they may not use highlights the growing tension between AI’s energy demands and grid capacity. According to TechCrunch reporting, data center demand is expected to increase nearly threefold over the next decade, with much of this growth driven by AI applications.
This infrastructure challenge isn’t just theoretical – it directly impacts companies like Chai that rely on massive computational resources. “Every line of code in our codebase is homegrown,” said Chai co-founder Jack Dent. “We’re not taking LLMs off the shelf that are in the open source ecosystem and fine-tuning them. These are highly custom architectures.” Such custom architectures require significant computing power, creating a ripple effect through the energy sector.
Broader Industry Context
Chai’s deal with Eli Lilly comes amid a broader industry shift toward AI-driven drug discovery. Just before announcing the Chai partnership, Eli Lilly revealed a separate $1 billion collaboration with NVIDIA to create an AI drug discovery lab in San Francisco. This “co-innovation lab” will combine big data, compute resources, and scientific expertise in an attempt to accelerate medicine development.
Meanwhile, OpenAI – where Chai’s founders got their start – has been making its own infrastructure moves. The AI giant recently signed a multi-year agreement worth over $10 billion with chipmaker Cerebras for 750 megawatts of compute starting in 2026. “OpenAI’s compute strategy is to build a resilient portfolio that matches the right systems to the right workloads,” said Sachin Katti, OpenAI’s head of infrastructure. “Cerebras adds a dedicated low-latency inference solution to our platform.”
Skepticism and Realistic Expectations
Despite the enthusiasm from investors and pharmaceutical partners, some industry veterans remain skeptical. Traditional drug development is notoriously difficult, with high failure rates and timelines that can stretch over a decade. Some experts question whether AI technologies, while promising, can truly overcome these fundamental challenges.
Aliza Apple, head of Lilly’s TuneLab program, expressed measured optimism: “By combining Chai’s generative design models with Lilly’s deep biologics expertise and proprietary data, we intend to push the frontier of how AI can design better molecules from the outset, with the ultimate goal to help accelerate the development of innovative medicines for patients.”
Ethical and Practical Considerations
The rapid adoption of AI in critical areas like healthcare raises important questions about safety and oversight. While Chai focuses on drug discovery, other AI applications have faced scrutiny. OpenAI recently announced it would begin testing ads in ChatGPT for free and Go-tier users, framing this as necessary to sustain free access while generating revenue. The company promised “answer independence,” meaning ads won’t influence chatbot responses, but the move highlights the balancing act between innovation, accessibility, and commercialization.
More seriously, AI companies face legal challenges related to product safety. Multiple wrongful death lawsuits have been filed against OpenAI following suicides allegedly encouraged by ChatGPT interactions. While these cases involve consumer-facing AI rather than drug discovery tools, they underscore the broader responsibility that comes with deploying powerful AI systems.
The Road Ahead
For Chai and similar companies, the path forward involves navigating multiple challenges simultaneously. They must demonstrate that their AI models can reliably produce viable drug candidates, secure the computational resources needed for their work, and operate within an increasingly complex regulatory and ethical landscape.
“There are no fundamental barriers to deployment of these models in drug discovery,” said General Catalyst’s Viboch. “Companies will still need to take drug candidates through testing and clinical trials, but we believe there’ll be significant advantages to those who adopt these technologies – not just in compressing discovery timelines, but also in unlocking classes of medicines that have historically been difficult to develop.”
As the industry watches Chai’s partnership with Eli Lilly unfold, several key questions remain: Can AI truly revolutionize drug discovery, or will it become another tool in the pharmaceutical toolkit? How will energy constraints impact the scalability of these computational approaches? And what safeguards need to be in place as AI takes on increasingly critical roles in healthcare? The answers to these questions will shape not just Chai’s future, but the trajectory of an entire industry at the intersection of technology and medicine.